BCC 2023 | Remaining questions regarding the use of frontline CDK4/6 inhibitors and endocrine therapy

Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, provides expert insights on remaining questions surrounding the use of frontline CDK4/6 inhibitors in combination with endocrine therapy, discussing the latest data on the efficacy and safety of CDK4/6 inhibitors and important unanswered questions, including relapse following adjuvant therapy, the optimal endocrine therapy backbone, as well as further combination approaches with targeted therapies such as capivasertib.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.